CELL U RITE NATURALS - Trademark Details
Status: 710 - Cancelled - Section 8
Serial Number
85474481
Registration Number
4460807
Word Mark
CELL U RITE NATURALS
Status
710 - Cancelled - Section 8
Status Date
2020-08-14
Filing Date
2011-11-16
Registration Number
4460807
Registration Date
2014-01-07
Mark Drawing
3000 - Illustration: Drawing or design which also includes word(s)/ letter(s)/number(s)
Typeset
Design Searches
050308, 050310, 050325, 100901, 260321, 261126, 261127 - More than one leaf, including scattered leaves, bunches of leaves not attached to branches. Other branches with leaves, with or without fruit. Other leaves. Medicines and nonmedical products in tablet, capsule or powder form; suppositories. Ovals that are completely or partially shaded. Oblongs as carriers for words, letters or designs. Oblongs not being used as carriers for words, letters or designs.
Published for Opposition Date
2013-08-27
Attorney Name
Law Office Assigned Location Code
L50
Employee Name
DUBRAY, KATHERINE M
Statements
Indication of Colors claimed
Color is not claimed as a feature of the mark.
Disclaimer with Predetermined Text
"NATURALS"
Description of Mark
The mark consists of the stylized wording "CELL U RITE NATURALS" and a design comprised of a first leaf to the left of a second leaf, with the leaves situated above the center of an oblong that is divided in the middle by a curved separation, with the curved line formed by the separation of the sides of the oblong appearing to meet with the leaves in a manner suggesting that the leaves are on a stem, with the wording "CELL U RITE" appearing across the oblong design and the word "NATURALS" appearing beneath the oblong design.
Goods and Services
Goods containing or prepared from natural ingredients, namely, meal replacement powders, meal replacement bars, nutritional supplement energy bars, dietary fiber as a food additive, protein supplement shakes, meal replacement drinks, vitamin enhanced water, electrolyte drinks for medical purposes to treat dehydration, dietary supplements for promoting weight loss, herbal supplements for the promotion of healthy liver function, herbal supplements for the treatment of arthritis, herbal supplements for the treatment of cardiovascular disease, herbal supplements for the treatment of dental and oral diseases, herbal supplements for the treatment of headaches, herbal supplements for the treatment of cold and flu, herbal supplements for treating urinary tract infections, herbal supplements for the treatment of inflammatory diseases, namely, inflammatory bowel diseases and inflammatory connective tissue diseases, herbal supplements for the treatment of the musculoskeletal system, namely, connective tissue diseases, cartilage injuries, herbal supplements for the treatment of asthma, sinusitis, herbal supplements for use in dermatology, namely, acne, dermatitis, eczema, psoriasis, dietary supplement to treat digestive system discomforts, namely, blood sugar regulation, acid reflux, irritable bowel syndrome, herbal supplements to treat female hormonal imbalance, herbal supplements to treat mood disorders, edible fish oils for medical purposes, dietary and nutritional supplements containing omega fatty acids, mineral supplements, nutritional supplements for building body mass, dietary and food supplements containing whey, soy, rice, pea, and/or canola, vitamin supplements, dietary and herbal supplements to enhance energy and performance, medicated skin care preparations, pharmaceutical preparations for the relief of pain, pharmaceutical preparations for the treatment of acne, pharmaceutical preparations for the treatment of allergies, pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections, pharmaceutical preparations for the treatment of cardiovascular diseases, pharmaceutical preparations for the treatment of carpal tunnel syndrome, pharmaceutical preparations for the treatment of chronic pain, pharmaceutical preparations for the treatment of dental and oral diseases, pharmaceutical preparations for the treatment of diabetes, pharmaceutical preparations for the treatment of gastro-intestinal diseases, pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases, pharmaceutical preparations for the treatment of glaucoma, pharmaceutical preparations for the treatment of headaches, pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes, pharmaceutical preparations for the treatment of infectious diseases, namely, respiratory infections, eye infections, pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases, pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely, diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, pharmaceutical preparations for the treatment of metabolic disorders, namely, diabetes, bulimia nervosa, anorexia, obesity and hypothyroidism, pharmaceutical preparations for the treatment of migraine, pharmaceutical preparations for the treatment of motion sickness, pharmaceutical preparations for the treatment of myalgia and neuralgia, pharmaceutical preparations for the treatment of neurological diseases, namely, preparations for treatment of Alzheimer's disease, Huntington's disease and cerebral palsy, pharmaceutical preparations for the treatment of ophthalmological diseases and disorders, pharmaceutical preparations for the treatment of physical and psychological addictions, namely, gambling addiction, eating disorders and addictions, nicotine addiction, internet addiction, drug addiction, pharmaceutical preparations for the treatment of psychiatric and other brain diseases and disorders, namely, anxiety, mood disorders, schizophrenia, cognitive and bipolar disorders, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, multiple sclerosis, seizures, pharmaceutical preparations for the treatment of psychiatric diseases, namely, mood disorders, anxiety disorders, cognitive disorders, schizophrenia, pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections, pharmaceutical preparations for the treatment of skin irritations, namely, bee stings, sunburn, rashes, sores, corns, calluses, and acne, pharmaceutical preparations for the treatment of smoking cessation, pharmaceutical preparations for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, pharmaceutical preparations for the treatment of the central nervous system, namely, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, pharmaceutical preparations for the treatment of the musculoskeletal system, namely, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries, pharmaceutical preparations for the treatment of the respiratory system, pharmaceutical preparations for the treatment of varicose veins, pharmaceutical preparations for the treatment of vascular diseases, pharmaceutical preparations for the treatment of viral diseases, namely, herpes, hepatitis, acquired immune deficiency syndrome (aids), pharmaceutical preparations for use in dermatology, namely, dermatitis, skin pigmentation diseases, sexually transmitted diseases, pharmaceutical preparations for use in gastroenterology, pharmaceutical preparations for use in ocular disorders, pharmaceutical preparations for use in oncology, pharmaceutical preparations for use in ophthalmology, radioactive pharmaceutical preparations for in vivo diagnostic or therapeutic use
Pseudo Mark
CELL YOU RITE NATURALS
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
006, 018, 044, 046, 051, 052
Class Status Code
2 - Sec. 8 - Entire Registration
Class Status Date
2020-08-14
Primary Code
005
Correspondences
Name
L. S. VANLANDINGHAM III
Address
Please log in with your Justia account to see this address.
Foreign Application Information
| Filing Date | Application Number | Country | Foreign Priority Claim In |
| 2011-10-14 | 1547767 | Canada | True |
| Canada | False | ||
| Canada | False |
Trademark Events
| Event Date | Event Description |
| 2011-11-19 | NEW APPLICATION ENTERED IN TRAM |
| 2011-11-22 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
| 2011-11-23 | NOTICE OF DESIGN SEARCH CODE MAILED |
| 2012-02-07 | TEAS VOLUNTARY AMENDMENT RECEIVED |
| 2012-02-15 | ASSIGNED TO LIE |
| 2012-02-27 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| 2012-02-27 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| 2012-03-02 | ASSIGNED TO EXAMINER |
| 2012-03-06 | NON-FINAL ACTION WRITTEN |
| 2012-03-06 | NON-FINAL ACTION E-MAILED |
| 2012-03-06 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| 2012-05-03 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| 2012-05-10 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| 2012-05-10 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| 2012-06-01 | SUSPENSION LETTER WRITTEN |
| 2012-06-01 | LETTER OF SUSPENSION E-MAILED |
| 2012-06-01 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| 2012-12-06 | LIE CHECKED SUSP - TO ATTY FOR ACTION |
| 2013-01-02 | SUSPENSION INQUIRY WRITTEN |
| 2013-01-02 | INQUIRY TO SUSPENSION E-MAILED |
| 2013-01-02 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED |
| 2013-01-03 | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED |
| 2013-01-08 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| 2013-01-08 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| 2013-01-29 | ASSIGNED TO EXAMINER |
| 2013-01-29 | SUSPENSION LETTER WRITTEN |
| 2013-01-29 | LETTER OF SUSPENSION E-MAILED |
| 2013-01-29 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| 2013-04-23 | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED |
| 2013-04-30 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| 2013-04-30 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| 2013-05-21 | NON-FINAL ACTION WRITTEN |
| 2013-05-21 | NON-FINAL ACTION E-MAILED |
| 2013-05-21 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| 2013-05-24 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| 2013-05-30 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| 2013-05-30 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| 2013-06-17 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| 2013-06-19 | LAW OFFICE PUBLICATION REVIEW COMPLETED |
| 2013-06-28 | WITHDRAWN FROM PUB - OG REVIEW QUERY |
| 2013-07-11 | PREVIOUS ALLOWANCE COUNT WITHDRAWN |
| 2013-07-18 | NON-FINAL ACTION WRITTEN |
| 2013-07-18 | NON-FINAL ACTION E-MAILED |
| 2013-07-18 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| 2013-07-19 | EXAMINERS AMENDMENT -WRITTEN |
| 2013-07-19 | EXAMINERS AMENDMENT E-MAILED |
| 2013-07-19 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| 2013-07-19 | EXAMINER'S AMENDMENT ENTERED |
| 2013-07-22 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| 2013-07-23 | LAW OFFICE PUBLICATION REVIEW COMPLETED |
| 2013-08-07 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| 2013-08-27 | PUBLISHED FOR OPPOSITION |
| 2013-08-27 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 2013-10-22 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| 2013-10-22 | TEAS DELETE 1(B) BASIS RECEIVED |
| 2013-11-27 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| 2013-10-22 | NOTICE OF ALLOWANCE CANCELLED |
| 2013-11-27 | 1(B) BASIS DELETED; PROCEED TO REGISTRATION |
| 2014-01-07 | REGISTERED-PRINCIPAL REGISTER |
| 2016-02-08 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| 2019-01-07 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED |
| 2020-08-14 | CANCELLED SEC. 8 (6-YR) |
